Last Call!与专家面对面探讨分享肿瘤临床项目数据管理的经验与体会 —— DIA肿瘤临床研究中的数据管理研讨会

2019-11-04 佚名 DIA订阅号

为提高我国肿瘤临床试验数据管理的质量,分享肿瘤项目数据管理的经验与体会,DIA 将于2019年11月15-16日在上海浦东淳大万丽酒店举办第二届《肿瘤临床研究中的数据管理》研讨会。 在本次研讨会中,我们将分析目前肿瘤临床试验的现状, 特别是对数据管理人员所面临的挑战,进行研讨并提出应对措施。 主要内容包括研究中心源数据规范化采集与管理,确保源数据的准确;良好的CRF设计以支持多种试验设计;高效省时

为提高我国肿瘤临床试验数据管理的质量,分享肿瘤项目数据管理的经验与体会,DIA 将于2019年11月15-16日在上海浦东淳大万丽酒店举办第二届《肿瘤临床研究中的数据管理》研讨会。

在本次研讨会中,我们将分析目前肿瘤临床试验的现状, 特别是对数据管理人员所面临的挑战,进行研讨并提出应对措施。 主要内容包括研究中心源数据规范化采集与管理,确保源数据的准确;良好的CRF设计以支持多种试验设计;高效省时与灵活的逻辑核查与数据清理方法,解决EDC系统上线前的压力;以及跨部门的良好协作,多方位提高临床数据的质量。此外,我们还将讨论影像学以及中心试验室等外部数据的管理,数据管理人员的专业知识的积累,使用灵活实用的软件工具,并支持临床操作以及项目质量的改善与提高。研讨会还将如何应用建立数据湖(Data Lake),加速肿瘤临床试验的数据采集、报告与提交等话题展开讨论。

在线注册 (在线注册请长按识别左侧二维码)

11月15-16日 | 上海浦东淳大万丽酒店

展商联系人:谢飞
电话: 010-57042652
邮箱: fei.xie@diaglobal.org

会议日程


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1712160, encodeId=7d051e12160af, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Mon Jun 15 20:53:00 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639253, encodeId=42111639253a8, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Dec 20 02:53:00 CST 2019, time=2019-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994833, encodeId=31fa199483344, content=<a href='/topic/show?id=3d51e345936' target=_blank style='color:#2F92EE;'>#研讨会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73459, encryptionId=3d51e345936, topicName=研讨会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Sat Jan 25 05:53:00 CST 2020, time=2020-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329302, encodeId=aabe13293020d, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Wed Nov 06 05:53:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492425, encodeId=277314924252a, content=<a href='/topic/show?id=a0445e76182' target=_blank style='color:#2F92EE;'>#数据管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57761, encryptionId=a0445e76182, topicName=数据管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e6e8929353, createdName=waiwai3033, createdTime=Wed Nov 06 05:53:00 CST 2019, time=2019-11-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1712160, encodeId=7d051e12160af, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Mon Jun 15 20:53:00 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639253, encodeId=42111639253a8, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Dec 20 02:53:00 CST 2019, time=2019-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994833, encodeId=31fa199483344, content=<a href='/topic/show?id=3d51e345936' target=_blank style='color:#2F92EE;'>#研讨会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73459, encryptionId=3d51e345936, topicName=研讨会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Sat Jan 25 05:53:00 CST 2020, time=2020-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329302, encodeId=aabe13293020d, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Wed Nov 06 05:53:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492425, encodeId=277314924252a, content=<a href='/topic/show?id=a0445e76182' target=_blank style='color:#2F92EE;'>#数据管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57761, encryptionId=a0445e76182, topicName=数据管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e6e8929353, createdName=waiwai3033, createdTime=Wed Nov 06 05:53:00 CST 2019, time=2019-11-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1712160, encodeId=7d051e12160af, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Mon Jun 15 20:53:00 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639253, encodeId=42111639253a8, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Dec 20 02:53:00 CST 2019, time=2019-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994833, encodeId=31fa199483344, content=<a href='/topic/show?id=3d51e345936' target=_blank style='color:#2F92EE;'>#研讨会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73459, encryptionId=3d51e345936, topicName=研讨会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Sat Jan 25 05:53:00 CST 2020, time=2020-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329302, encodeId=aabe13293020d, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Wed Nov 06 05:53:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492425, encodeId=277314924252a, content=<a href='/topic/show?id=a0445e76182' target=_blank style='color:#2F92EE;'>#数据管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57761, encryptionId=a0445e76182, topicName=数据管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e6e8929353, createdName=waiwai3033, createdTime=Wed Nov 06 05:53:00 CST 2019, time=2019-11-06, status=1, ipAttribution=)]
    2020-01-25 kcb069
  4. [GetPortalCommentsPageByObjectIdResponse(id=1712160, encodeId=7d051e12160af, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Mon Jun 15 20:53:00 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639253, encodeId=42111639253a8, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Dec 20 02:53:00 CST 2019, time=2019-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994833, encodeId=31fa199483344, content=<a href='/topic/show?id=3d51e345936' target=_blank style='color:#2F92EE;'>#研讨会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73459, encryptionId=3d51e345936, topicName=研讨会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Sat Jan 25 05:53:00 CST 2020, time=2020-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329302, encodeId=aabe13293020d, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Wed Nov 06 05:53:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492425, encodeId=277314924252a, content=<a href='/topic/show?id=a0445e76182' target=_blank style='color:#2F92EE;'>#数据管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57761, encryptionId=a0445e76182, topicName=数据管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e6e8929353, createdName=waiwai3033, createdTime=Wed Nov 06 05:53:00 CST 2019, time=2019-11-06, status=1, ipAttribution=)]
    2019-11-06 膀胱癌
  5. [GetPortalCommentsPageByObjectIdResponse(id=1712160, encodeId=7d051e12160af, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Mon Jun 15 20:53:00 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639253, encodeId=42111639253a8, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Dec 20 02:53:00 CST 2019, time=2019-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994833, encodeId=31fa199483344, content=<a href='/topic/show?id=3d51e345936' target=_blank style='color:#2F92EE;'>#研讨会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73459, encryptionId=3d51e345936, topicName=研讨会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Sat Jan 25 05:53:00 CST 2020, time=2020-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329302, encodeId=aabe13293020d, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Wed Nov 06 05:53:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492425, encodeId=277314924252a, content=<a href='/topic/show?id=a0445e76182' target=_blank style='color:#2F92EE;'>#数据管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57761, encryptionId=a0445e76182, topicName=数据管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e6e8929353, createdName=waiwai3033, createdTime=Wed Nov 06 05:53:00 CST 2019, time=2019-11-06, status=1, ipAttribution=)]

相关资讯

2017中国国际药物信息大会暨第九届DIA中国年会,在沪盛大召开

2017年5月21日-24日《2017中国国际药物信息大会暨第九届DIA中国年会》在中国上海举行。DIA(Drug Information Association,药物信息协会)是一个全球性、中立的组织,旨在为业界提供自由交流和分享知识信息的平台,促进医疗产品的创新和开发。第九届DIA中国年会以“恪守临床价值导向,引领药物研发新趋势” 为主题,以回归“临床价值”这一药物研发本质,夯实新药研发基础,

5.20-23:见证2019年DIA中国年会的高光时刻

★ 多形式 ★有效交流与学习★ 多专题 ★聚焦行业热点★ 多大咖 ★面对面深度分享★ 多干货 ★会前研讨重实操★ 多经典 ★ICH主题日精彩继续★ 多互动 ★学术社区交流与分享★ 多精彩 ★见证行业的力量★ 多参与 ★现在就行动在线注册在线注册截止日:5月15日(本届会议不开放现场注册/缴费)在线注册请长按识别下方二维码中文日程下载,请长按识别下方二维码2019 DIA中国年会2019年5月20-

适应时代变革,提高MA业务能力,DIA为您打造全方位医学事务培训

为推动全球医学事务发展和医学事务工作人员业务素质和技能提高,DIA在全球和中国展开了形式多样的交流活动。每年的DIA中国年会,一直是医学事务专业人士齐聚一堂展开交流和辩论的平台;2015年12月,DIA中国组织了第一期医学事务研讨班,在会议的基础上又深化了医学事务相关话题探讨,得到了业界的一致认可,也形成了DIA中国医学事务培训的雏形;与此同时,DIA在全球也有丰富的为各大药企定制化MA 内训的经